Secondary analyses showed significant effects on plasma TGs ( change from baseline to 9 mo : WEP , -28.9 7.7 mg/dL ; EP , 8.5 10.9 mg/dL ; P = 0.03 ) and metabolic syndrome ( MetS ) prevalence at 9 mo ( WEP : 18.1 % ; EP : 37.7 % ; P = 0.02 ) among obese participants .